|
1
|
Webb PM and Jordan SJ: Epidemiology of
epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:3–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fathalla MF: Incessant ovulation--a factor
in ovarian neoplasia? Lancet. 2:1631971. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cramer DW and Welch WR: Determinants of
ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl
Cancer Inst. 71:717–721. 1983.PubMed/NCBI
|
|
4
|
Orr B and Edwards RP: Diagnosis and
treatment of ovarian cancer. Hematol Oncol Clin North Am.
32:943–964. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu TX, Rothenberg ME and Micro RNA:
MicroRNA. J Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thorsen SB, Obad S, Jensen NF, Stenvang J
and Kauppinen S: The therapeutic potential of microRNAs in cancer.
Cancer J. 18:275–284. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nana-Sinkam SP and Croce CM: Clinical
applications for microRNAs in cancer. Clin Pharmacol Ther.
93:98–104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tutar L, Tutar E, Özgür A and Tutar Y:
Therapeutic Targeting of microRNAs in Cancer: Future Perspectives.
Drug Dev Res. 76:382–388. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhong LN, Zhang YZ, Li H, Fu HL, Lv CX and
Jia XJ: Overexpressed miR-196a accelerates osteogenic
differentiation in osteoporotic mice via GNAS-dependent Hedgehog
signaling pathway. J Cell Biochem. 120:19422–19431. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ren W, Wu S, Wu Y, Liu T, Zhao X and Li Y:
MicroRNA-196a/-196b regulate the progression of hepatocellular
carcinoma through modulating the JAK/STAT pathway via targeting
SOCS2. Cell Death Dis. 10:3332019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fan Y, Fan J, Huang L, Ye M, Huang Z, Wang
Y, Li Q and Huang J: Increased expression of microRNA-196a predicts
poor prognosis in human ovarian carcinoma. Int J Clin Exp Pathol.
8:4132–4137. 2015.PubMed/NCBI
|
|
13
|
Lukács J, Soltész B, Penyige A, Nagy B and
Póka R: Identification of miR-146a and miR-196a-2 single nucleotide
polymorphisms at patients with high-grade serous ovarian cancer. J
Biotechnol. 297:54–57. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang B, Li SZ, Ma L, Liu HL, Liu J and
Shao JJ: Expression and mechanism of action of miR-196a in
epithelial ovarian cancer. Asian Pac J Trop Med. 9:1105–1110. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Su CY, Lin TC, Lin YF, Chen MH, Lee CH,
Wang HY, Lee YC, Liu YP, Chen CL and Hsiao M: DDX3 as a strongest
prognosis marker and its downregulation promotes metastasis in
colorectal cancer. Oncotarget. 6:18602–18612. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Botlagunta M, Vesuna F, Mironchik Y, Raman
A, Lisok A, Winnard P Jr, Mukadam S, Van Diest P, Chen JH,
Farabaugh P, et al: Oncogenic role of DDX3 in breast cancer
biogenesis. Oncogene. 27:3912–3922. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Blomquist CH, Leung BS, Zhang R, Zhu Y and
Chang PM: Properties and regulation of 17 β-hydroxysteroid
oxidoreductase of OVCAR-3, CAOV-3, and A431 cells: Effects of
epidermal growth factor, estradiol, and progesterone. J Cell
Biochem. 59:409–417. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheung LWT, Leung PCK and Wong AST:
Gonadotropin-releasing hormone promotes ovarian cancer cell
invasiveness through c-Jun NH2-terminal kinase-mediated activation
of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res.
66:10902–10910. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
You S, Wang F, Hu Q, Li P, Zhang C, Yu Y,
Zhang Y, Li Q, Bao Q, Liu P, et al: Abnormal expression of YEATS4
associates with poor prognosis and promotes cell proliferation of
hepatic carcinoma cell by regulation the TCEA1/DDX3 axis. Am J
Cancer Res. 8:2076–2087. 2018.PubMed/NCBI
|
|
21
|
Kim MJ, Lee SJ, Ryu JH, Kim SH, Kwon IC
and Roberts TM: Combination of KRAS gene silencing and PI3K
inhibition for ovarian cancer treatment. J Control Release.
318:98–108. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Patch AM, Christie EL, Etemadmoghadam D,
Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey
PJ, et al Australian Ovarian Cancer Study Group, : Whole-genome
characterization of chemoresistant ovarian cancer. Nature.
521:489–494. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He Y, Zhang D, Yang Y, Wang X, Zhao X,
Zhang P, Zhu H, Xu N and Liang S: A double-edged function of DDX3,
as an oncogene or tumor suppressor, in cancer progression (Review).
Oncol Rep. 39:883–892. 2018.(Review). PubMed/NCBI
|
|
24
|
Heerma van Voss MR, Schrijver WA, Ter
Hoeve ND, Hoefnagel LD, Manson QF, van der Wall E, Raman V and van
Diest PJ; Dutch Distant Breast Cancer Metastases Consortium, : The
prognostic effect of DDX3 upregulation in distant breast cancer
metastases. Clin Exp Metastasis. 34:85–92. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gai M, Bo Q and Qi L: Epigenetic
down-regulated DDX10 promotes cell proliferation through Akt/NF-κB
pathway in ovarian cancer. Biochem Biophys Res Commun.
469:1000–1005. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Han C, Liu Y, Wan G, Choi HJ, Zhao L, Ivan
C, He X, Sood AK, Zhang X and Lu X: The RNA-binding protein DDX1
promotes primary microRNA maturation and inhibits ovarian tumor
progression. Cell Rep. 8:1447–1460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Carnero A and Paramio JM: The
PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Front Oncol.
4:2522014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wise HM, Hermida MA and Leslie NR:
Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond).
131:197–210. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakahata S, Ichikawa T, Maneesaay P, Saito
Y, Nagai K, Tamura T, Manachai N, Yamakawa N, Hamasaki M,
Kitabayashi I, et al: Loss of NDRG2 expression activates PI3K-AKT
signalling via PTEN phosphorylation in ATLL and other cancers. Nat
Commun. 5:33932014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xia M, Tong JH, Ji NN, Duan ML, Tan YH and
Xu JG: Tramadol regulates proliferation, migration and invasion via
PTEN/PI3K/AKT signaling in lung adenocarcinoma cells. Eur Rev Med
Pharmacol Sci. 20:2573–2580. 2016.PubMed/NCBI
|
